CIK 0001770069 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
MapLight Therapeutics, Inc.
Sign in to watch- Ticker
- MPLT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 832163243
- Phone
- 650-839-4360
- Business address
- 800 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
- Former names
- Alvarado Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,256,232
- in 7 filings, $193K under 10b5-1 plans
Net −$1,256,232. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Kroeger Christopher A. −$595K Chief Executive Officer sold 6% of stake
- Hanson Kristopher −$266K General Counsel sold 17% of stake
- Foff Erin Pennock −$124K Chief Medical Officer sold 5% of stake
- Kreitzer Anatol −$96K Chief Discovery Officer sold 7% of stake
- Lillie James Woodruff −$93K Chief Scientific Officer sold 5% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-15 | Malenka Robert C. Director | Sale 10b5-1 | −8,593 | $26.90 | $231K | 316,466 |
| 2026-04-15 | Hanson Kristopher General Counsel | Sale | −1,529 | $26.80 | $41K | 190,463 |
| 2026-04-15 | Lillie James Woodruff Chief Scientific Officer | Sale | −1,730 | $26.82 | $46K | 297,940 |
| 2026-04-15 | GILLIS JONATHAN CAAO and PAO | Sale | −3,590 | $26.61 | $96K | 251,054 |
| 2026-04-15 | Kroeger Christopher A. Chief Executive Officer | Sale | −9,135 | $26.93 | $246K | 1,640,616 |
| 2026-02-24 | Malenka Robert C. Director | Sale | −736 | $18.15 | $13K | 325,059 |
| 2026-02-23 | Malenka Robert C. Director | Sale | −10,788 | $18.39 | $198K | 326,271 |
| 2026-02-23 | Malenka Robert C. Director | Sale | −476 | $19.06 | $9K | 325,795 |
| 2026-02-20 | Malenka Robert C. Director | Sale | −2,195 | $18.03 | $40K | 337,059 |
| 2026-02-20 | Pavlov George Director | Purchase | +9,920 | $17.86 | $177K | 25,000 |
| 2026-02-19 | Pavlov George Director | Purchase | +4,422 | $17.57 | $78K | 15,080 |
| 2026-02-18 | Pavlov George Director | Purchase | +10,658 | $17.48 | $186K | 10,658 |
| 2026-02-13 | Malenka Robert C. Director | Sale | −12,116 | $18.21 | $221K | 339,254 |
| 2026-02-11 | Malenka Robert C. Director | Sale | −241 | $18.00 | $4K | 351,370 |
| 2026-02-10 | Malenka Robert C. Director | Sale | −6,622 | $18.12 | $120K | 351,611 |
| 2026-02-10 | Garnett Timothy John Director | Purchase | +14,124 | $17.89 | $253K | 14,124 |
| 2026-02-05 | Setia Vishwas Chief Financial Officer | Grant or award | +7,730 | 395,549 | ||
| 2026-02-05 | Setia Vishwas Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +31,395 | 31,395 | ||
| 2026-02-05 | Kreitzer Anatol Chief Discovery Officer | Grant or award | +6,020 | 259,928 | ||
| 2026-02-05 | Kreitzer Anatol Chief Discovery Officer | Grant or award · Employee Stock Option (right to buy) | +24,455 | 24,455 |
Page 9 of 12 · 239 trades